Compounds > formic acid

Page last updated: 2024-10-16

formic acid and Chronic Illness

formic acid has been researched along with Chronic Illness in 1 studies

formic acid: RN given refers to parent cpd
formic acid : The simplest carboxylic acid, containing a single carbon. Occurs naturally in various sources including the venom of bee and ant stings, and is a useful organic synthetic reagent. Principally used as a preservative and antibacterial agent in livestock feed. Induces severe metabolic acidosis and ocular injury in human subjects.

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Trompetter, I	1
Lebert, J	1
Weiß, G	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Observational Study With PASCALLERG ® in Patients With Hay Fever[NCT01660737]				123 participants (Actual)	Observational	2012-02-29	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change of Symptom Bronchial Complaints (Pre-post)

Request Scale (0=not present, 1=mild, 2=moderate, 3=strong) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	deterioreated
PASCALLERG® Tablets in Patients With Hay Fever	44	7	3

Change of Symptom Burning Eyes (Pre-post)

Request Scale (0=not present, 1=mild, 2=moderate, 3=strong) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	deteriorated
PASCALLERG® Tablets in Patients With Hay Fever	68	6	2

Change of Symptom Dry Eyes (Pre- Post)

Request Scale (0=not present, 1=mild, 2=moderate, 3=strong) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	deteriorated
PASCALLERG® Tablets in Patients With Hay Fever	36	9	0

Change of Symptom Headache (Pre-post)

Request Scale (0=not present, 1=mild, 2=moderate, 3=strong) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	deteriorated
PASCALLERG® Tablets in Patients With Hay Fever	38	15	0

Change of Symptom Itching Eyes (Pre- Post)

Request Scale (0=not present, 1=mild, 2=moderate, 3=strong) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	deteriorated
PASCALLERG® Tablets in Patients With Hay Fever	87	10	4

Change of Symptom Rhinitis (Pre-post)

Request Scale (0=not present, 1=mild, 2=moderate, 3=strong) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	deteriorated
PASCALLERG® Tablets in Patients With Hay Fever	89	8	5

Change of Symptom Sneezing (Pre-post)

Request Scale (0=not present, 1=mild, 2=moderate, 3=strong) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	deteriorated
PASCALLERG® Tablets in Patients With Hay Fever	87	13	7

Change of Symptom Tearing Eyes (Pre-post)

Request Scale (0=not present, 1=mild, 2=moderate, 3=strong) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	deteriorated
PASCALLERG® Tablets in Patients With Hay Fever	70	7	5

Change of Symtom Fatigue / Tiredness

Request Scale (0=not present, 1=mild, 2=moderate, 3=strong) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	deteriorated
PASCALLERG® Tablets in Patients With Hay Fever	77	11	5

Efficacy of Pascallerg

Request of Efficacy using a 4-stage scale (very good efficacy, good efficacy, moderate efficacy, no efficacy) (NCT01660737)
Timeframe: appr. 4 weeks after baseline (after appr. 4 weeks of treatment)

Intervention	participants (Number)
	Very good efficacy (symptoms complete decline)	Good efficacy (symptoms clearly improved)	Moderate efficacy (smptoms slightly improved)	No efficacy (symptoms unchanged o worsend)	No data available
PASCALLERG® Tablets in Patients With Hay Fever	60	44	15	2	2

Numerical Rating Scale Well Beeing (Pre- Post)

Influence of allergy on the general well-being (scale from 0-no influence to 10 strong influence) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	detoriorated
PASCALLERG® Tablets in Patients With Hay Fever	109	4	2

Tolerability of Pascallerg

Request of Tolerability using a 2-stage scale (very good tolerability, bad tolerability) (NCT01660737)
Timeframe: app. 4 weeks after baseline (treatment app. for 4 weeks)

Intervention	participants (Number)
	Very good	Bad tolerability
PASCALLERG® Tablets in Patients With Hay Fever	122	1

Other Studies

1 other study available for formic acid and Chronic Illness

Article	Year
Homeopathic complex remedy in the treatment of allergic rhinitis: results of a prospective, multicenter observational study. Forschende Komplementarmedizin (2006), 2015, Volume: 22, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Chromium Compounds; Chronic Disease; Complementar	2015